Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Signal pathway and mechanism of MUC1-C regulating TNBC Occurrence and progression (Comprehensive arrangement according to the published articles).

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques:

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Schematic illustration of MUC1-C shRNA@Fe 3 O 4 MNPs construction and the therapeutic mechanism on TNBC. MUC1-C shRNA and Fe 3 O 4 MNPs were self-assembled into MUC1-C shRNA@ Fe 3 O 4 MNPs by electrostatic adsorption. After entering TNBC cells and under the action of AMF, on the one hand, it induces apoptosis and ferroptosis by targeting MUC1-C, on the other hand, it increases the temperature (43 °C) and the Fe 2+ concentration directly kills TNBC cells and stimulates apoptosis and ferroptosis mechanisms.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Adsorption, Concentration Assay

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( D ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ). IHC results of MUC1 in TNBC tissues, paraneoplastic tissues and normal breast tissues ( F ). Error bars represent means ± SD. **p<0.01, ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: Expressing

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Silence efficiency of MUC1-C shRNA on TNBC cell line HCC-70. RT-qPCR ( A ) and Western blot detected the silencing efficiency of MUC1-C shRNA ( B and C ). MUC1-C shRNA (3#) plasmid map ( D ) and target sequence (the highlighted yellow section) ( E ). Error bars represent means ± SD. ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Quantitative RT-PCR, Western Blot, Plasmid Preparation, Sequencing

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Characterization of MUC1-C shRNA@Fe 3 O 4 MNPs. Appearance ( A ) and TEM image ( D ) of the prepared MUC1-C shRNA@Fe 3 O 4 MNPs. DSL Size distribution of Fe 3 O 4 MNPs ( B and C ) and MUC1-C shRNA@Fe 3 O 4 MNPs ( E and F ). Tyndall effect of MUC1-C shRNA@Fe 3 O 4 MNPs ( G ). Zeta potential of MUC1-C shRNA@Fe 3 O 4 MNPs ( H ). Encapsulation efficiency at different shRNA/MNPs ratios ( I ). TEM elemental mapping analysis of MUC1-C shRNA@Fe 3 O 4 MNPs ( J ). Raman spectrum of MUC1-C shRNA, Fe 3 O 4 MNPs, and MUC1-C shRNA@Fe 3 O 4 MNPs ( K ). Release profiles of Fe 2+ from MUC1-C shRNA@Fe 3 O 4 MNPs at different pH values with or without AMF ( L ). The heating curves of MUC1-C shRNA@Fe 3 O 4 MNPs with different concentrations (50–250μg/mL) ( M ). Hemolysis test at different concentrations (MUC1-C shRNA@Fe 3 O 4 MNPs) (n=3) ( N and O ). Hemolysis test (200μg/mL, n=3) ( P and Q ). Error bars represent means ± SD. TEM scale bar: 50nm.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Zeta Potential Analyzer, Encapsulation

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Cellular uptake of NPs. Cellular uptake of MUC1-C shRNA@Fe 3 O 4 MNPs in the HCC-70 cells was observed under a CLSM. Green fluorescence indicates MUC1-C shRNA@Fe 3 O 4 -FITC and blue fluorescence indicates the nucleus ( A ). Investigation of internalization pathway of MUC1-C shRNA@Fe 3 O 4 MNPs in HCC-70 cells in the presence of different endocytosis inhibitors (n=3) ( B ). Error bars represent means ± SD. Scale bar: 50μm. ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Fluorescence

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: MUC1-C shRNA@Fe 3 O 4 MNPs suppress the migration, invasion, and proliferation in HCC-70 cell lines. Wound healing ( A ), Transwell ( B ), CCK-8 OD 450nm ( C ), and inhibition rate based on CCK-8 ( D and E ). The protein bands ( F ) and quantitative statistical results ( G ) of Bax, cleaved-caspase3, GPX4, NRF2, and FTH1 of HCC-70 cell lines (n=3). Error bars represent means ± SD. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Migration, CCK-8 Assay, Inhibition

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: The in vivo therapeutic effects of the MUC1-C shRNA@Fe 3 O 4 MNPs on TNBC. IR thermal images of TNBC-bearing C-NKG mice with local injection of MUC1-C shRNA@Fe 3 O 4 MNPs (200 µg mL −1 ), or normal saline under AMF (3Kw) ( A ). Images ( B ) and weights ( C ) of xenograft tumors harvested from the mice after various treatments on the 25th day. Tumor volumes ( D ) and Body weight ( E ) growth in mice were measured after different treatments every 5 days within 25 days (n=4). Prussian blue reaction of tumor tissue showing iron staining and tumor necrosis, labeled area was typical necrosis (200x) ( F ). Expression of Bax, cleaved-caspase 3, GPX4, NRF2, and FTH1 in tumor tissues ( G ). Quantitative statistical results according to the protein bands ( H ). Error bars represent means ± SD. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: In Vivo, shRNA, Injection, Saline, Staining, Labeling, Expressing

Journal: International Journal of Nanomedicine

Article Title: The Therapeutic Effects of MUC1-C shRNA@Fe 3 O 4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer

doi: 10.2147/IJN.S426849

Figure Lengend Snippet: Serum biochemistry indicators assessment of TNBC mice (n=4). Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Total bilirubin (TBIL). Blood urea nitrogen (BUN), Creatinine (CR) ( A ). Effect of MUC1-C shRNA@Fe 3 O 4 MNPs on the histopathology of heart, lung, spleen, Kidney, and liver from TNBC mice ( B ). Error bars represent means ± SD. Scale bar: 100μm.

Article Snippet: Figure 1 MUC1 and its expressions in various types of tumors (from UCSC genome browser on human, the red pentagram indicates breast invasive carcinoma) ( A ), MUC1 protein expression in different tumor cell lines ( B ) and BRCA cell lines ( C ) (based on datasets of Human Protein Atlas), MUC1 expression between BRCA and normal tissue ( ) (based on datasets of The Cancer Genome Atlas), MUC1 expression in normal human breast cell (MCF-10A) and TNBC cell lines (BT-20, MDA-MB-231, MDA-MB-468, HCC-70) ( E ).

Techniques: shRNA, Histopathology

Journal: ACS Omega

Article Title: Modified Sanliangsan Improved Sjogren’s Syndrome Complicated with Interstitial Lung Disease by Suppressing Serum MUC1 Levels

doi: 10.1021/acsomega.4c01147

Figure Lengend Snippet: SP treatment suppresses hub SS-related MUC1 expression to improve SS-ILD. (A, B) Volcano plots display the DEGs in the salivary gland (A) and parotid (B) of patients with SS. The hub genes associated with SS are labeled by a black arrow. (C) Venn diagram displays the hub DEGs shared in the salivary gland, peripheral blood, and parotid of patients with SS. The DEGs from the salivary gland, peripheral blood, and parotid are represented by orange, gray, and blue circles, respectively. (D) Topological protein–protein interaction network of hub DEGs associated with SS. (E) Relative expression levels of APP and MUC1 in patients with SS-ILD vs healthy individuals. (F) Expression level of MUC1 in serum of patients with SS-ILD before and after SP and CK treatments. (G) ELISA of the serum protein levels of MUC1 in patients with SS-ILD before and after SP and CK treatments; “NS: no significance; * P < 0.05; ** P < 0.01”.

Article Snippet: The recombinant MUC1 protein was obtained by GST-tag protein purification kit (Beyotime Biotechnology, Shanghai, China), then collected, and dialyzed in PBS glycerol buffer.

Techniques: Expressing, Labeling, Enzyme-linked Immunosorbent Assay

Journal: ACS Omega

Article Title: Modified Sanliangsan Improved Sjogren’s Syndrome Complicated with Interstitial Lung Disease by Suppressing Serum MUC1 Levels

doi: 10.1021/acsomega.4c01147

Figure Lengend Snippet: SP therapy improves SS-LID by affecting the regulation network of MUC1 . (A) Scatter plot displays the pathway enrichment results of transcriptome profiles of the peripheral blood of patients with SS. The plot size and color represent the gene number and significance of each pathway. (B) Protein–protein interaction network showing the potential regulator of MUC1. (C) Expression of genes interacting with MUC1 in the serum of patients with SS-ILD after SP therapy.

Article Snippet: The recombinant MUC1 protein was obtained by GST-tag protein purification kit (Beyotime Biotechnology, Shanghai, China), then collected, and dialyzed in PBS glycerol buffer.

Techniques: Expressing

Journal: ACS Omega

Article Title: Modified Sanliangsan Improved Sjogren’s Syndrome Complicated with Interstitial Lung Disease by Suppressing Serum MUC1 Levels

doi: 10.1021/acsomega.4c01147

Figure Lengend Snippet: Network pharmacology analysis of SP in improving SS-ILD. (A) Category of metabolites from SP. (B) KEGG pathways analysis on targets of bioactive compounds of SP. (C) Integrated network of bioactive compounds and related proteins. (D) Molecular docking analysis detects the interaction between MUC1 protein and eugenol. (E) Isothermal titration calorimetry (ITC) enthalpograms of eugenol binding to MUC1. Titration data are presented as blue plots and fit as a black solid line. (F) RT-qPCR determines the effects of eugenol in affecting abnormal upregulation of genes involved in SS-ILD pathogenesis.

Article Snippet: The recombinant MUC1 protein was obtained by GST-tag protein purification kit (Beyotime Biotechnology, Shanghai, China), then collected, and dialyzed in PBS glycerol buffer.

Techniques: Isothermal Titration Calorimetry, Binding Assay, Titration, Quantitative RT-PCR